Stelis Biopharma and Pieris, a next generation therapeutic protein R&D firm, have started a long-term collaboration for clinical development and commercialization of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology.
The partnership deploys the synergies of Pieris' new drug discovery and early development capabilities with Stelis' strong bio-manufacturing and clinical development expertise.
As part the deal, Pieris will advance each collaborative program via in vivo proof of concept, at which stage Stelis will be responsible for drug manufacturing and advancing the molecule through a first-in-human clinical study.
After positive clinical data, both the firms will co-develop programs under a joint venture.
Stelis CEO Anand Iyer said the alliance with Pieris shows how the company's strategic investments into manufacturing facilities are attracting partners with cutting edge biologics such as Anticalins, which hold great promise in the ophthalmic space.
"Today's announcement is another example of how Pieris is finding innovative structures and committed partners to advance several Anticalins to the clinic in areas of high unmet need," Iyer said.
"Our strategic relationship with Stelis provides access to bio-manufacturing capabilities of the highest standard, yet in a very cost-effective manner."
Stelis is a subsidiary of Strides Arcolab, which is focused on biotherapeutic drug development and bio-manufacturing.
